Background: We aim to characterize breast management for patients with genetic mutations and concurrent breast cancer (BC) or prior BC treatment.
Methods: Adults with a BC-related mutation and prior/concurrent BC diagnosis were identified. Groups were stratified by mutation type [BRCA1/2, high penetrance mutation (HPM), moderate penetrance mutation (MPM)] and timing of genetic testing (concurrent with BC versus after BC treatment). Outcomes were compared.
Results: Among 338 patients included, 63 % had BRCA1/2 mutations, 9 % HPM, and 28 % MPM. Approximately 38 % had testing concurrent with a BC diagnosis and 62 % after BC treatment. Patients with concurrent testing favored bilateral mastectomy (57 %) versus 26 % lumpectomy, and 16 % unilateral mastectomy, which varied by mutation type. Patients previously treated preferred surveillance (92 % vs. 8 % additional surgery), regardless of mutation type.
Conclusion: The timing of a significant BC-related genetic test result and mutation type may be associated with management decisions among patients with breast cancer.
Keywords: BRCA; Breast cancer; Cancer genetics; Mastectomy; Prophylactic mastectomy; Risk reducing mastectomy.
Copyright © 2024 Elsevier Inc. All rights reserved.